Chai Discovery

Chai Discovery is an AI structural-biology company building foundation models for molecular design. Its Chai-1 model predicts biomolecular structures, in the lineage of AlphaFold, and its 2025 Chai-2 model performs fully de-novo antibody design — generating novel antibodies against a target from scratch, reportedly at meaningful hit rates, a hard and commercially valuable problem. Backed by OpenAI and others and valued at roughly 1.3 billion dollars, Chai offers its models as accessible tools to researchers, positioning itself as infrastructure for antibody and protein discovery rather than a drug-development company. As with all generative-design AI in biology, designed candidates are starting points that require experimental validation; the promise is dramatically expanding the space of viable molecules a team can explore.